Skip to main content

Telerehabilitation

0
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Verona Pharma
Verona PharmaUK - London
1 program
Cognitive treatment delivered via telerehabilitation.N/A1 trial
Active Trials
NCT06964581Recruiting60Est. Sep 2025
Frontera Therapeutics
Frontera TherapeuticsChina - Suzhou
1 program
TeleCIMTN/A1 trial
Active Trials
NCT04877418Completed22Est. Aug 2022
Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
1 program
occupation-based teleinterventionN/A1 trial
Active Trials
NCT05564871Not Yet Recruiting40Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Verona PharmaCognitive treatment delivered via telerehabilitation.
Jerusalem Pharmaceuticalsoccupation-based teleintervention
Frontera TherapeuticsTeleCIMT

Clinical Trials (3)

Total enrollment: 122 patients across 3 trials

NCT06964581Verona PharmaCognitive treatment delivered via telerehabilitation.

Cognitive Rehabilitation of Deficits in Patients With Multiple Sclerosis

Start: Feb 2023Est. completion: Sep 202560 patients
N/ARecruiting
NCT05564871Jerusalem Pharmaceuticalsoccupation-based teleintervention

Effectiveness of Occupational Therapy Teleintervention in Pediatric

Start: Oct 2022Est. completion: Jun 202640 patients
N/ANot Yet Recruiting

Tele-rehabilitation Through CIMT at Recovering the Function of the Upper Limb and Quality of Life

Start: May 2022Est. completion: Aug 202222 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 122 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.